MAPK3 and prostate cancer: Among these cascades, the ERK1/2 and PI3K pathways are hyperactivated in prostate cancer and enhanced activation of ERK1/2 and PI3Ks is correlated with disease progression, androgen independence, and poor prognosis (33, 34, 35, 36).